| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Jineol targets multiple cellular pathways involved in cell survival and proliferation. As a natural product, it likely interacts with various cellular targets including enzymes, receptors, and signaling molecules. Jineol has been shown to exhibit cytotoxic activity against cancer cells and induce apoptosis. The compound's specific molecular targets have not been fully characterized, but its anti-cancer activity suggests involvement in apoptosis and cell cycle regulation pathways.
|
|---|---|
| ln Vitro |
In vitro, Jineol exhibits potent cytotoxic activity against various cancer cell lines. It induces apoptosis in cancer cells, demonstrating anti-cancer activity. Jineol's cytotoxicity makes it a valuable tool for studying natural product-based anti-cancer agents. However, specific IC50 values or detailed activity data is not provided in the available sources.
|
| ln Vivo |
In vivo, Jineol has been studied for its anti-cancer activity. However, specific in vivo efficacy data from animal models is not detailed in the available sources. The compound is for research use only and not for therapeutic applications.
|
| Enzyme Assay |
For Jineol, standard cell-free assays include enzyme inhibition assays for targets such as kinases or other enzymes involved in cell survival and proliferation. The compound's ability to inhibit these enzymes can be measured using appropriate substrates and detection methods.
|
| Cell Assay |
For Jineol, standard cellular assays involve treatment of cancer cell lines with the test compound for 24-72 hours. Cell viability is measured using MTT or CellTiter-Glo assays to determine IC50 values. Apoptosis is assessed by Annexin V/PI staining, caspase activity assays, and DNA fragmentation. Cell cycle analysis is performed by flow cytometry.
|
| Animal Protocol |
For in vivo evaluation of Jineol, standard animal models include tumor xenograft models using cancer cell lines sensitive to the compound. The compound is typically administered orally or intraperitoneally for 2-4 weeks. Tumor growth, apoptosis markers, and survival are assessed.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Jineol is not provided in the available sources. As a natural product with moderate lipophilicity, it would be expected to have reasonable cell permeability. Comprehensive pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for Jineol is not provided in the available sources. As a natural product, comprehensive toxicological evaluation would be required for therapeutic development. The compound is for research use only and not for therapeutic applications.
|
| References | |
| Additional Infomation |
Jineol is a dihydroxyquinoline with hydroxyl groups at positions 3 and 8 of its quinoline ring. It was isolated from the centipede (Scolopendra subspinipes) and exhibits cytotoxic activity against human tumor cell lines. Jineol can be used both as a metabolite and as an antitumor drug. It is a quinoline alkaloid, belonging to the quinoline class of compounds, and is also a dihydroxyquinoline. There are reports on Jineol in Scolopendra subspinipes, and relevant data are available for reference.
Jineol is a natural product isolated from the centipede Scolopendra subspinipes mutilans. It has been studied for its cytotoxic and anti-cancer activities, exhibiting potent cytotoxicity against various cancer cell lines. No regulatory approval has been identified. |
| Molecular Formula |
C9H7NO2
|
|---|---|
| Molecular Weight |
161.16
|
| Exact Mass |
161.048
|
| CAS # |
178762-28-2
|
| PubChem CID |
177338
|
| Appearance |
Off-white to pink solid powder
|
| Density |
1.418g/cm3
|
| Boiling Point |
397.2ºC at 760mmHg
|
| Flash Point |
194ºC
|
| Vapour Pressure |
7.08E-07mmHg at 25°C
|
| Index of Refraction |
1.742
|
| LogP |
1.646
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IGDFDIZIHMFYGR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H7NO2/c11-7-4-6-2-1-3-8(12)9(6)10-5-7/h1-5,11-12H
|
| Chemical Name |
quinoline-3,8-diol
|
| Synonyms |
NSC694081; NSC 694081; Jineol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~620.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2050 mL | 31.0251 mL | 62.0501 mL | |
| 5 mM | 1.2410 mL | 6.2050 mL | 12.4100 mL | |
| 10 mM | 0.6205 mL | 3.1025 mL | 6.2050 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
